Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.75 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.55 |
| ▸ | HRH1 | P35367 | 3/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19405149 | 0.90 | TLR7 (1.00) | TLR7TLR9KIT | |
| SCHEMBL19405193 | 0.88 | TLR9 (0.80) | TLR7TLR9 | |
| SCHEMBL19405236 | 0.88 | TLR7 (0.78) | TLR7TLR9HRH4HRH1EHMT2 | |
| SCHEMBL19385200 | 0.86 | TLR9 (1.00) | TLR7TLR9 | |
| SCHEMBL19385233 | 0.86 | TLR7 (0.75) | TLR7TLR9HRH4EHMT2KIT | |
| SCHEMBL20838519 | 0.83 | TLR9 (0.72) | TLR7TLR9KIT | |
| SCHEMBL19405239 | 0.78 | TLR7 (0.78) | TLR7TLR9EHMT2 | |
| SCHEMBL20838528 | 0.76 | TLR7 (0.75) | TLR7TLR9KIT | |
| SCHEMBL19385129 | 0.76 | TLR7 (1.00) | TLR7TLR9EHMT2 | |
| SCHEMBL19385020 | 0.76 | TLR9 (1.00) | TLR7TLR9EHMT2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-05-26 | — | — | US | disclosed |
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-03-28 | — | — | US | disclosed |
| WO-2017163264-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | TLR9, TLR1, TLR3 | TLR7 5/4885TLR9 1/4885HRH4 58/4885 |
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | TLR9, TLR1, TLR3 | TLR7 4/4885TLR9 1/4885HRH4 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.